Beijing Leadman Biochemistry Co Ltd

The company's capital structure is characterized by a high proportion of equity, with total equity of 1,639,117,550 CNY and total liabilities of 137,078,390 CNY, resulting in a debt-to-equity ratio of 0.0. Despite a negative net income of -22,983,070 CNY, the company maintains a strong liquidity position, as evidenced by a current ratio of 12.71. However, the company's free cash flow is minimal at 817,250 CNY, and operating cash flow is 29,163,630 CNY, indicating limited cash generation capacity. Profitability metrics show a challenging performance, with a return on equity (ROE) of -0.014 and a return on assets (ROA) of -0.0129, both significantly below the industry median for medical equipment and supplies. Gross profit of 151,175,020 CNY represents 46.3% of revenue, but the company's operating income is negative at -17,853,220 CNY, indicating operational inefficiencies. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment and supplies sector. Looking ahead, the company's revenue is expected to grow from 326,306,440 CNY to 654,804,220 CNY, representing a significant increase of 100.7%. However, the company's negative net income and operating income suggest that this growth may not yet be translating into profitability. The company faces moderate liquidity risk, as indicated by a negative net cash position after subtracting total debt. While dilution risk is currently low, the company's capital expenditure of -17,589,000 CNY suggests ongoing investment in operations, which could affect future liquidity. No recent events or filings have been disclosed that would significantly alter the company's risk profile. Recent financial filings and transcripts do not indicate any material changes in the company's operations or strategic direction. The company's focus remains on its core medical equipment and supplies business, with no new product lines or geographic expansions disclosed in the available data.